• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Immunol . Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan

tetano

Editor, Senior Moderator
Int Immunol


. 2021 Feb 4;dxab005.
doi: 10.1093/intimm/dxab005. Online ahead of print.
Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan


Tomohiro Takano[SUP] 1 [/SUP], Takayuki Matsumura[SUP] 1 [/SUP], Yu Adachi[SUP] 1 [/SUP], Kazutaka Terahara[SUP] 1 [/SUP], Saya Moriyama[SUP] 1 [/SUP], Taishi Onodera[SUP] 1 [/SUP], Ayae Nishiyama[SUP] 1 [/SUP], Ai Kawana-Tachikawa[SUP] 2 [/SUP], Shoji Miki[SUP] 2 [/SUP], Kaori Hosoya-Nakayama[SUP] 2 [/SUP], Midori Nakamura-Hoshi[SUP] 2 [/SUP], Sayuri Seki[SUP] 2 [/SUP], Natsuo Tachikawa[SUP] 3 [/SUP], Yukihiro Yoshimura[SUP] 3 [/SUP], Nobuyuki Miyata[SUP] 3 [/SUP], Hiroshi Horiuchi[SUP] 3 [/SUP], Hiroaki Sasaki[SUP] 3 [/SUP], Kazuhito Miyazaki[SUP] 3 [/SUP], Noriko Kinoshita[SUP] 4 [/SUP], Tsutomu Sudo[SUP] 4 [/SUP], Yutaro Akiyama[SUP] 4 [/SUP], Rubuna Sato[SUP] 4 [/SUP], Tadaki Suzuki[SUP] 5 [/SUP], Tetsuro Matano[SUP] 2 [/SUP], Yoshimasa Takahashi[SUP] 1 [/SUP]



Affiliations

Abstract

An expanded myeloid cell compartment is a hallmark of severe coronavirus disease 2019 (COVID-19). However, data regarding myeloid cell expansion have been collected in Europe, where the mortality rate by COVID-19 is greater than those in other regions including Japan. Thus, characteristics of COVID-19-induced myeloid cell subsets remain largely unknown in the regions with low mortality rates. Here, we analyzed cellular dynamics of myeloid-derived suppressor cell (MDSC) subsets and examined whether any of them correlate with disease severity and prognosis, using blood samples from Japanese COVID-19 patients. We observed that polymorphonuclear (PMN)-MDSCs, but not other MDSC subsets, transiently expanded in severe cases but not in mild or moderate cases. Contrary to previous studies in Europe, this subset selectively expanded in survivors of severe cases and subsided before discharge, but such transient expansion was not observed in non-survivors in Japanese cohort. Analysis of plasma cytokine/chemokine levels revealed positive correlation of PMN-MDSC frequencies with interleukin 8 (IL-8) levels prior to the cell expansion, indicating the involvement of IL-8 on recruitment of PMN-MDSCs to peripheral blood following the onset of severe COVID-19. Thus, our data indicates that transient expansion of the PMN-MDSC subset results in improved clinical outcome. Thus, this myeloid cell subset may be a predictor of prognosis in cases of severe COVID-19 in Japan.

Keywords: Chemokine; Cytokine; Innate immunity; Myeloid-derived suppressor cell; SARS-CoV-2
 
Back
Top Bottom